The event will discuss current thinking on biomarkers, clinical outcome scales, and other endpoints to contextualize data that was recently presented at the International Congress of Parkinson’s ...
Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.
BETHESDA, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
BETHESDA, Md. - Gain Therapeutics, Inc. (NASDAQ:GANX), a $69 million market cap biotech company currently trading at $1.92 per share, announced Monday that its lead drug candidate GT-02287 showed ...
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) ...
As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid ...
BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
A new method that successfully designs serine hydrolase enzymes capable of catalyzing ester hydrolysis with high efficiency, demonstrates a computational approach for creating de novo enzymes that ...
Cells can’t operate without the power supplied by working mitochondria. When the mechanisms that replicate or repair mitochondrial DNA (mtDNA) fail, it can cause a wide range of syndromes for which ...
CCM Biosciences has developed groundbreaking compounds that activate the enzyme SIRT3, potentially reversing age-related cellular decline. These first-in-class drugs outperform existing treatments and ...
Researchers present novel therapeutics that rejuvenate a previously undruggable mitochondrial regulator of aging through a new mode of enzyme activation. Leveraging a newly identified biophysical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback